Frassoni F, Scarpati D, Bacigalupo A, Vitale V, Corvo R, Miceli S, Gualandi F, Occhini D, Clavio M, van Lint M T
Centro-Trapianti Midollo Osseo, Ospedale San Martino, Genova, Italy.
Br J Haematol. 1989 Oct;73(2):211-6. doi: 10.1111/j.1365-2141.1989.tb00254.x.
One-hundred and five patients undergoing allogeneic bone marrow transplantation (BMT) for acute myeloid leukaemia (AML) (n = 61) and chronic myeloid leukaemia (n = 44) were analysed for risk factors associated with relapse. All patients received marrow from an HLA identical sibling after preparation with cyclophosphamide 120 mg/kg and total body irradiation (TBI) 330 cGy on each of the three days prior to transplantation. There was a difference of +/- 18% between the nominal total dose of 990 cGy and the actual dose received as indicated by dosimetric recordings. While interstitial pneumonitis had minimal impact on survival (4%) there was a considerable difference in the incidence of relapses. The incidence of relapse was 55% versus 11% in patients receiving less or more than 990 cGy respectively and this had a major impact on survival (38% v. 74% at 7 years) since transplant-related mortality was comparable in the two groups. A multivariate Cox analysis indicated that a lower TBI dose (less than 990 cGy) was the most significant factor associated with relapse and the second most important factor associated with recurrence of leukaemia was the absence of chronic graft-versus-host-disease (cGvHD). Actuarial relapse incidence was 62%. 28% and 18% for patients with no, limited or extensive chronic GvHD respectively. However, chronic GVHD had no significant impact on survival. Combined stratification for TBI dose and cGvHD showed that the dose effect of TBI on relapse was evident both in patients with and without cGvHD. Chronic GvHD influenced the risk of relapse only in patients receiving less than 990 cGy. These results suggest that a higher dose of TBI, within this schedule, produced long-term disease-free survival in the majority of AMLs and CMLs. Minor radiobiological side effects were experienced but a small reduction of the dose may significantly increase the risk of relapse.
对105例接受异基因骨髓移植(BMT)治疗急性髓系白血病(AML)(n = 61)和慢性髓系白血病(n = 44)的患者进行了复发相关危险因素分析。所有患者在移植前三天每天接受120 mg/kg环磷酰胺和330 cGy全身照射(TBI)预处理后,接受来自HLA匹配同胞的骨髓。名义总剂量990 cGy与剂量测定记录所示实际接受剂量之间相差±18%。虽然间质性肺炎对生存率影响极小(4%),但复发率存在显著差异。接受低于或高于990 cGy的患者复发率分别为55%和11%,这对生存率有重大影响(7年时分别为38%对74%),因为两组的移植相关死亡率相当。多变量Cox分析表明,较低的TBI剂量(低于990 cGy)是与复发相关的最显著因素,与白血病复发相关的第二重要因素是无慢性移植物抗宿主病(cGvHD)。精算复发率分别为62%、28%和18%,分别对应无、有限或广泛慢性移植物抗宿主病的患者。然而,慢性移植物抗宿主病对生存率无显著影响。TBI剂量和cGvHD的联合分层显示,TBI对复发的剂量效应在有和无cGvHD的患者中均明显。慢性移植物抗宿主病仅在接受低于990 cGy的患者中影响复发风险。这些结果表明,在此方案中,较高剂量的TBI可使大多数AML和CML患者实现长期无病生存。虽有轻微的放射生物学副作用,但剂量的小幅降低可能会显著增加复发风险。